NEXVIAZYME

sanofi-aventis canada inc🇨🇦 Health Canada

Approval Id: 53674eb40a165345
Drug Approval Canada Name: NEXVIAZYME
Product Name: NEXVIAZYME
Status: Marketed
Status Date: 2022-02-09
Original Market Date: 2022-02-09
Din: 02522365
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Schedule D , Prescription
Ahfs: 44:00.00
Atc Original: A16AB22 AVALGLUCOSIDASE ALFA
Atc Name: a 16 ab 22
Aig Number: 0163274001
Company Name: sanofi-aventis canada inc
Company Address: 1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4

AVALGLUCOSIDASE ALFA

100 MG / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

53674eb40a165345

Type

Standard